Enovis, Formerly Branded DJO®, Introduces Arsenal Ankle Plating System™

A comprehensive ankle plating portfolio, designed with the proven technology of Arsenal Foot Plating System, expands offerings to address both tri-malleolar and intra-articular fracture patterns

DJO® is now part of the Enovis™ family.*

Enovis Corporation, an innovation-driven medical technology growth company, announced today the launch of the Arsenal Ankle Plating System™. This system consists of 37 anatomically designed plates throughout nine plate families, offering a plating solution for any ankle fracture.

The Arsenal Ankle Plating System is the latest addition to Enovis’ suite of foot and ankle products and an expansion of Arsenal Foot Plating System, leveraging its history of proven results and pioneering technology.

“I am excited to see the technological advancements and trusted results from the Arsenal Foot Plating system applied to a broader set of indications throughout the ankle,” stated Matthew Herring, MD. “The plates are stout where it matters and sleek where needed, which makes a difference when treating complex ankle and distal tibia fractures in the OR.”

The variable angle locking technology, allowing a 60° cone of angulation, multi-lock functionality, accepting repeatable lock and relock of screw to plate interface, and dual lead screws that the Arsenal Ankle Plating System offers, makes for a powerful combination of patented and innovative solutions addressing all types of fracture personalities.

“Our Arsenal product line was created to disrupt existing technology,” said Gary Justak, President and General Manager of Enovis Foot & Ankle. “In addition to the standard ankle fracture plating options available today, this system features multiple solutions for malleoli fractures including a modernized spin of the proven AO technique of tension band wiring. These are just a couple of reasons why we are proud to introduce this system as we continue our growth journey in the Foot & Ankle market.”

SourceEnovis

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”